

Olcegepant

Catalog No: tcsc0360



Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

204697-65-4

Formula:

$C_{38}H_{47}Br_2N_9O_5$

Pathway:

GPCR/G Protein;Neuronal Signaling

Target:

CGRP Receptor;CGRP Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 50 mg/mL (57.49 mM)

Alternative Names:

BIBN-4096;BIBN 4096BS

Observed Molecular Weight:

869.65

Product Description


Olcegepant is the first potent and selective non-peptide antagonist of the **calcitonin gene-related peptide 1 (CGRP1) receptor** with **IC₅₀** of 0.03 nM and with a **K_i** of 14.4 pM for human CGRP.

IC50 & Target: IC50: 0.03 nM (CGRP1)^[1]

Ki: 14.4 pM (hCGRP)^[2]

In Vitro: Olcegepant possesses higher affinity for the human CGRP receptor than the endogenous ligand CGRP and 150-fold higher affinity compared to the peptidic antagonist CGRP8-37. Olcegepant reverses CGRP-mediated vasodilation in human cerebral vessels and inhibits neurogenic vasodilation in a surrogate animal model of migraine pathophysiology^[1]. Olcegepant (BIBN4096BS) is extremely potent at primate CGRP receptors exhibiting an affinity (K_i) for human CGRP receptors of 14.4±6.3 (n=4) pM^[2]. Several lines of evidence suggest that a calcitonin-gene related peptide (CGRP) receptor antagonist may serve as a novel abortive migraine treatment. Olcegepant (BIBN4096BS) exhibits competitive antagonism at the CGRP receptor present in SK-N-MC cells. Isolated human cerebral, coronary, and omental arteries are studied with a sensitive myograph technique. CGRP induces a concentration-dependent relaxation that is antagonized by Olcegepant in a competitive manner^[3].

In Vivo: Olcegepant (BIBN4096BS) in doses between 1 and 30 µg/kg (i.v.) inhibits the effects of CGRP, released by stimulation of the trigeminal ganglion, on facial blood flow in marmoset monkeys^[2]. Pre-treatment with Olcegepant (900 µg/kg) inhibits the capsaicin-induced expression of Fos throughout the spinal trigeminal nucleus by 57%. In contrast, the expression of phosphorylated extracellular signal-regulated kinase in the trigeminal ganglion is not changed by Olcegepant pre-treatment^[4]. Olcegepant (0.3 to 0.9 mg/kg, i.v.) markedly reduces mechanical allodynia in CCI-ION rats. Olcegepant (0.6 mg/kg, i.v.) significantly reduces the number of c-Fos immunolabeled cells in spinal nucleus of the trigeminal nerve and upregulation of ATF3 transcript (a marker of neuron injury) but not that of interleukin-6 in trigeminal ganglion of CCI-ION rats^[5].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!